REGENXBIO Clears Path for Accelerated FDA Review of MPS II Gene Therapy
Event summary
- FDA aligns with REGENXBIO on accelerated approval pathway for NAVSUNLI™ (RGX-121) without requiring additional studies.
- REGENXBIO plans to resubmit BLA in Q3 2026 following a Type A meeting expected in July 2026.
- NAVSUNLI is the first potential one-time gene therapy for Mucopolysaccharidosis II (MPS II), an ultra-rare neurodegenerative disease.
- Approval could result in a Priority Review Voucher (PRV) retained fully by REGENXBIO.
The big picture
REGENXBIO's alignment with the FDA on NAVSUNLI reflects a broader industry shift toward expedited pathways for rare disease treatments. The strategic partnership with Nippon Shinyaku positions REGENXBIO to capitalize on potential approvals, while the focus on gene therapy underscores its leadership in AAV-based treatments. Success here could validate its pipeline and attract further investment.
What we're watching
- Regulatory Dynamics
- How the FDA's commitment to rare disease therapies under accelerated approval will impact review timelines and success rates.
- Commercialization Strategy
- Whether NS Pharma can effectively commercialize NAVSUNLI in the U.S. following potential FDA approval.
- Pipeline Progress
- The pace at which REGENXBIO advances other gene therapies, including RGX-202 for Duchenne and RGX-111 for MPS I.
Related topics